Elinzanetant Effectively Reduces Vasomotor Symptoms in Breast Cancer Patients on Endocrine Therapy
A new phase 3 trial shows that elinzanetant significantly reduces hot flashes and night sweats in women undergoing endocrine therapy for breast cancer, improving quality of life.
A recent phase 3 clinical trial has demonstrated that elinzanetant, a neurokinin receptor-targeted medication, significantly decreases vasomotor symptoms such as hot flashes and night sweats in women undergoing endocrine therapy for hormone receptor-positive breast cancer. Published online on June 2, 2025, in the New England Journal of Medicine, the study was presented during the American Society of Clinical Oncology annual meeting held from May 31 to June 4 in Chicago.
The research was led by Dr. Fatima Cardoso from the Champalimaud Foundation in Lisbon, Portugal. It involved women aged 18 to 70 experiencing moderate-to-severe vasomotor symptoms linked to endocrine therapy either for breast cancer treatment or prevention. Participants were randomly assigned to receive daily doses of 120 mg of elinzanetant for 52 weeks or a placebo for the initial 12 weeks, followed by elinzanetant for 40 weeks. A total of 474 women participated, with only one using endocrine therapy for breast cancer prevention.
Results showed that women treated with elinzanetant had a greater reduction in vasomotor symptom frequency. At week 4, the average decline was 6.5 episodes per day compared to 3.0 episodes in the placebo group. By week 12, the reductions were 7.8 and 4.2 episodes, respectively. The study also noted that about 70% of women on elinzanetant experienced at least one adverse event, with serious adverse events occurring in 2.5% versus 0.6% in the placebo group. Despite this, the drug's benefits in alleviating symptoms and improving quality of life were deemed significant.
The authors highlighted that these findings are consistent with previous research in postmenopausal women, suggesting elinzanetant as a promising therapy for managing vasomotor symptoms. Certain authors disclosed financial ties to Bayer, the pharmaceutical company developing elinzanetant, which funded the study.
This innovative treatment offers hope for women suffering from menopause-like symptoms caused by cancer treatments, providing a new pathway to improve comfort and overall health during breast cancer management.
Source: https://medicalxpress.com/news/2025-06-elinzanetant-vasomotor-symptoms-women-breast.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Research Identifies PTP1B as a Key Target to Protect the Heart in Obesity and High-Fat Diet Conditions
Research from MMRI identifies PTP1B enzyme as a key driver in obesity-related heart dysfunction, opening new avenues for targeted therapy to protect cardiac health.
Innovative Method Reveals Causal Connections in Neuronal Activity Using Spike Train Data
A new method utilizing spike train data enables precise mapping of causal connections between neurons, enhancing our understanding of brain networks and neurological disorders.
Air Pollution Linked to Increased Risk of Developing Epilepsy
New research links long-term exposure to air pollution with a higher risk of developing epilepsy in adults, emphasizing the importance of environmental health policies for neurological disease prevention.
New Research Highlights How Diabetes Alters Heart Structure and Function
A recent study reveals how type 2 diabetes induces molecular and structural changes in the heart, increasing the risk of heart failure. Researchers highlight potential pathways for targeted therapies to improve cardiovascular outcomes in diabetic patients.